Research Triangle Park, NC — (Marketwired) – June 18, 2019 – Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated May 14, 2019 (the “Circular”) for the Annual General and Special Meeting of Shareholders were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held in New York, New York on June 18, 2019. Detailed results of the vote for the election of directors are set out below:
| Name of Nominee | Votes For | % Votes For | Votes Withheld | % Votes Withheld |
| Dr. Khalid Islam | 11,125,297 | 96.20% | 439,246 | 3.80% |
| Mr. Adrian Haigh | 10,996,521 | 95.09% | 568,022 | 4.91% |
| Mr. Chris A. Rallis | 11,394,527 | 98.53% | 170,016 | 1.47% |
| Mr. Marco Brughera | 11,373,256 | 98.35% | 191,287 | 1.65% |
| Mr. Rostislav Raykov | 11,458,060 | 99.08% | 106,483 | 0.92% |
Shareholders voted 97.35% in favour of appointing Haskell & White LLP as auditors and authorizing the directors to fix the auditor remuneration, 94.48% in favour of the compensation paid to the Company’s named executive officers, 99.38% in favour of voting on the compensation paid to the Company’s named executive officers on an annual basis, 79.94% in favour of approving the unallocated stock options under the Company’s amended and restated stock option plan (the “Stock Option Plan”), 93.95% in favour of an amendment to the Stock Option Plan and 96.36% in favour of the extension of certain outstanding options held by certain of the Company’s officers and directors.
For further information, please contact:
Rosty Raykov
Chief Executive Officer
Fennec Pharmaceuticals Inc.
T: (919) 636-5144